Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Case Report: Neurological adverse events in subject with myasthenia gravis after PCSK9 inhibitor administration

V. Adámková, M. Vitásková, JA. Hubáček

. 2024 ; 11 (-) : 1343775. [pub] 20240312

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu kazuistiky

Perzistentní odkaz   https://www.medvik.cz/link/bmc24005603

BACKGROUND: Myasthenia gravis is a rare chronic autoimmune neuromuscular disorder mainly caused by autoantibodies to the nicotinic acetylcholine receptor. Cholesterol is an essential molecule that affects the distribution and proper functioning of this receptor. Several reports have described the potential worsening of myasthenia gravis in patients treated with statins. CASE PRESENTATION: The patient was an obese 72 years old man, past smoker, diagnosed with ischaemic heart disease, type 2 diabetes mellitus and lipid metabolism disorder. Statin treatment was not implemented because of chronic myasthenia gravis and PCSK9i monotherapy [Repatha (evolucamab), 140 mg] was implemented to treat dyslipidaemia. Within 24 h after the first dose of PCSK9i the patient developed severe muscle weakness, joint pain, fever, and general discomfort, lasting for several days. Despite strong advice against the second dose administration, this was self-administered approximately 2 weeks later, leading to report significant worsening of the muscle problems, leading to the patient admittion to the neurology department where he was being treated for myasthenia gravis attack. CONCLUSION: Based on the neurologist's conclusion, it can be assumed that in this case, treatment with PCSK9i resulted in significant worsening of the patient's chronic disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24005603
003      
CZ-PrNML
005      
20240412130938.0
007      
ta
008      
240405e20240312sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fcvm.2024.1343775 $2 doi
035    __
$a (PubMed)38532873
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Adámková, Věra $u Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czechia $u Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czechia $u Faculty of Biomedical Engineering, Czech Technical University, Prague, Czechia
245    10
$a Case Report: Neurological adverse events in subject with myasthenia gravis after PCSK9 inhibitor administration / $c V. Adámková, M. Vitásková, JA. Hubáček
520    9_
$a BACKGROUND: Myasthenia gravis is a rare chronic autoimmune neuromuscular disorder mainly caused by autoantibodies to the nicotinic acetylcholine receptor. Cholesterol is an essential molecule that affects the distribution and proper functioning of this receptor. Several reports have described the potential worsening of myasthenia gravis in patients treated with statins. CASE PRESENTATION: The patient was an obese 72 years old man, past smoker, diagnosed with ischaemic heart disease, type 2 diabetes mellitus and lipid metabolism disorder. Statin treatment was not implemented because of chronic myasthenia gravis and PCSK9i monotherapy [Repatha (evolucamab), 140 mg] was implemented to treat dyslipidaemia. Within 24 h after the first dose of PCSK9i the patient developed severe muscle weakness, joint pain, fever, and general discomfort, lasting for several days. Despite strong advice against the second dose administration, this was self-administered approximately 2 weeks later, leading to report significant worsening of the muscle problems, leading to the patient admittion to the neurology department where he was being treated for myasthenia gravis attack. CONCLUSION: Based on the neurologist's conclusion, it can be assumed that in this case, treatment with PCSK9i resulted in significant worsening of the patient's chronic disease.
590    __
$a NEINDEXOVÁNO
655    _2
$a kazuistiky $7 D002363
700    1_
$a Vitásková, Martina $u Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Hubáček, Jaroslav A $u Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia $u Third Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czechia
773    0_
$w MED00198704 $t Frontiers in cardiovascular medicine $x 2297-055X $g Roč. 11 (20240312), s. 1343775
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38532873 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20240412130930 $b ABA008
999    __
$a ok $b bmc $g 2075970 $s 1215365
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 11 $c - $d 1343775 $e 20240312 $i 2297-055X $m Frontiers in cardiovascular medicine $n Front Cardiovasc Med $x MED00198704
LZP    __
$a Pubmed-20240405

Najít záznam

Citační ukazatele

Možnosti archivace